The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: A systematic review of the literature

European Urology

Volumn 66, Issue 2, 2014, Pages 191-199

  Gakis, Georgios ^a   Boorjian, Stephen A ^b   Briganti, Alberto ^c   Joniau, Steven ^d   Karazanashvili, Guram ^e   Karnes, R Jeffrey ^b   Mattei, Agostino ^f   Shariat, Shahrokh F ^g   Stenzl, Arnulf ^a   Wirth, Manfred ^h   Stief, Christian G ⁱ  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b MAYO CLINIC   (United States)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e Clinic of Urology SJC Modern Medical Technologies   (Georgia)

^f Department of Urology Kantonsspital Lucerne ^*  (Switzerland)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

ⁱ LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Androgen deprivation therapy; Imaging; Lymph node positive metastasis; Multimodality; Pelvic lymph node dissection; Prostate cancer; Radical prostatectomy; Radiotherapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGE; ANDROGEN DEPRIVATION THERAPY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMORBIDITY; DIAGNOSTIC IMAGING; HIGH RISK PATIENT; HUMAN; ILIAC ARTERY; LONG TERM SURVIVAL; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MEDLINE; NOMOGRAM; OVERALL SURVIVAL; PELVIS; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; RETROPERITONEUM; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; DISEASE FREE SURVIVAL; MALE; PATHOLOGY; PROSTATIC NEOPLASMS; SURVIVAL RATE;

CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; HUMANS; ILIAC ARTERY; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; PELVIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 84904035583     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.05.033     Document Type: Review

References (70)

1. P.C. Verhagen, F.H. Schröder, L. Collette, and C.H. Bangma Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review Eur Urol 58 2010 261 269
2. G.S. Gerber, R.A. Thisted, and G.W. Chodak et al. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis Eur Urol 32 1997 385 390
3. C.J. Ryan, M.R. Smith, J.S. de Bono COU-AA-302 Investigators Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 2013 138 148
4. I.F. Tannock, R. de Wit, W.R. Berry TAX 327 Investigators Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
5. D. Schilling, G. Gakis, U. Bökeler, A. Stenzl, M.A. Kuczyk, and A.S. Merseburger Secondary hormonal ablation in hormone-independent prostate cancer [in German] Urologe A 48 2009 183 188
6. M.O. Grimm, S. Kamphausen, H. Hugenschmidt, M. Stephan-Odenthal, R. Ackermann, and T.A. Vögeli Clinical outcome of patients with lymph node positive prostate cancer after radical prostatectomy versus androgen deprivation Eur Urol 41 2002 628 634
7. J. Engel, P.J. Bastian, and H. Baur et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer Eur Urol 57 2010 754 761
8. R. Ghavamian, E.J. Bergstralh, M.L. Blute, J. Slezak, and H. Zincke Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison J Urol 161 1999 1223 1227 discussion 1227-8
9. G. Gakis, J. Efstathiou, and S.P. Lerner et al. ICUD-EAU International Consultation on Bladder Cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder Eur Urol 63 2013 45 57
10. A. Liberati, D.G. Altman, and J. Tetzlaff et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration Ann Intern Med 151 2009 W65 W94
11. Oxford Centre for Evidence-based Medicine (CEBM) levels of evidence. CEBM Web site. www.cebm.net. Updated May 2009.
12. G.H. Mickisch, A. Garin, H. van Poppel, L. de Prijck, R. Sylvester European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial Lancet 358 2001 966 970
13. A. Elattar, A. Bryant, B.A. Winter-Roach, M. Hatem, and R. Naik Optimal primary surgical treatment for advanced epithelial ovarian cancer Cochrane Database Syst Rev 2011 CD007565
14. J.A. Cadeddu, A.W. Partin, J.I. Epstein, and P.C. Walsh Stage D1 (T1-3, N1-3, M0) prostate cancer: a case-controlled comparison of conservative treatment versus radical prostatectomy Urology 50 1997 251 255
15. H.G. Frohmüller, M. Theiss, A. Manseck, and M.P. Wirth Survival and quality of life of patients with stage D1 (T1-3 pN1-2 M0) prostate cancer. Radical prostatectomy plus androgen deprivation versus androgen deprivation alone Eur Urol 27 1995 202 206
16. L. Cheng, ZinckeH, M.L. Blute, E.J. Bergstralh, B. Scherer, and D.G. Bostwick Risk of prostate carcinoma death in patients with lymph node metastasis Cancer 91 2001 66 73
17. T. Steuber, L. Budäis, and J. Walz et al. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study BJU Int 107 2011 1755 1761
18. P. Bader, F.C. Burkhard, R. Markwalder, and U.E. Studer Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 169 2003 849 854
19. S. Joniau, C.Y. Hsu, P. Gontero, M. Spahn, and H. Van Poppel Radical prostatectomy in very high-risk localized prostate cancer: long-term outcomes and outcome predictors Scand J Urol Nephrol 46 2012 164 171
20. J. Song, M. Li, G.P. Zagaja, J.B. Taxy, A.L. Shalhav, and H.A. Al-Ahmadie Intraoperative frozen section assessment of pelvic lymph nodes during radical prostatectomy is of limited value BJU Int 106 2010 1463 1467
21. C. von Bodman, G. Godoy, and D.C. Chade et al. Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy J Urol 184 2010 143 148
22. W.R. Lee Improvement in prostate cancer survival over time: a 20-year analysis: the Will Rogers phenomenon returns Cancer J 18 2012 9 10
23. A.R. Feinstein, D. Sosin, and C.K. Wells The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer N Engl J Med 312 1985 1604 1608
24. A. Briganti, F.K.-H. Chun, and A. Salonia et al. A nomogram for staging of exclusive nonobturator lymph node metastases in men with localized prostate cancer Eur Urol 51 2007 112 120
25. A. Heidenreich, Z. Varga, and R. von Knobloch Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis J Urol 167 2002 1681 1686
26. J. Ji, H. Yuan, L. Wang, and J. Hou Is the impact of the extent of lymphadenectomy in radical prostatectomy related to the disease risk? A single center prospective study J Surg Res 178 2012 779 784
27. G. Godoy, C. von Bodman, and D.C. Chade et al. Pelvic lymph node dissection for prostate cancer: frequency and distribution of nodal metastases in a contemporary radical prostatectomy series J Urol 187 2012 2082 2086
28. A. Briganti, N. Suardi, and P. Capogrosso et al. Lymphatic spread of nodal metastases in high-risk prostate cancer: the ascending pathway from the pelvis to the retroperitoneum Prostate 72 2012 186 192
29. M. Golimbu, P. Morales, S. Al-Askari, and J. Brown Extended pelvic lymphadenectomy for prostatic cancer J Urol 121 1979 617 620
30. S. Joniau, L. Van den Bergh, and E. Lerut et al. Mapping of pelvic lymph node metastases in prostate cancer Eur Urol 63 2013 450 458
31. A. Mattei, F.G. Fuechsel, and N. Bhatta Dhar et al. The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study Eur Urol 53 2008 118 125
32. S.H. Warncke, A. Mattei, F.G. Fuechsel, S. Z'Brun, T. Krause, and U.E. Studer Detection rate and operating time required for γ probe-guided sentinel lymph node resection after injection of technetium-99m nanocolloid into the prostate with and without preoperative imaging Eur Urol 52 2007 126 132
33. D. Weckermann, R. Dorn, G. Holl, T. Wagner, and R. Harzmann Limitations of radioguided surgery in high-risk prostate cancer Eur Urol 51 2007 1549 1558
34. P. Rigatti, N. Suardi, and A. Briganti et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography Eur Urol 60 2011 935 943
35. D. Schilling, J. Hennenlotter, and K. Sotlar et al. Quantification of tumor cell burden by analysis of single cell lymph node disaggregates in metastatic prostate cancer Prostate 70 2010 1110 1118
36. A. Briganti, F. Abdollah, and A. Nini et al. Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection Eur Urol 61 2012 1132 1138
37. T. Budiharto, S. Joniau, and E. Lerut et al. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases Eur Urol 60 2011 125 130
38. M. Beheshti, L. Imamovic, and G. Broinger et al. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients Radiology 254 2010 925 933
39. T. Steuber, T. Schlomm, and H. Heinzer et al. [F(18)]-fluoroethylcholine combined in-line PET-CT scan for detection of lymph-node metastasis in high risk prostate cancer patients prior to radical prostatectomy: preliminary results from a prospective histology-based study Eur J Cancer 46 2010 449 455
40. D. Tilki, O. Reich, and A. Graser et al. 18F-fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent Eur Urol 63 2013 792 796
41. S. Jeschke, L. Lusuardi, A. Myatt, S. Hruby, C. Pirich, and G. Janetschek Visualisation of the lymph node pathway in real time by laparoscopic radioisotope- and fluorescence-guided sentinel lymph node dissection in prostate cancer staging Urology 80 2012 1080 1086
42. D. Schilling, U. Boekeler, and G. Gakis et al. Modified concept for radioisotope-guided sentinel lymph node dissection in prostate cancer World J Urol 28 2010 715 720
43. M. Triantafyllou, U.E. Studer, and F.D. Birkhäuser et al. Ultrasmall superparamagnetic particles of iron oxide allow for the detection of metastases in normal sized pelvic lymph nodes of patients with bladder and/or prostate cancer Eur J Cancer 49 2013 616 624
44. H.C. Thoeny, M. Triantafyllou, and F.D. Birkhaeuser et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients Eur Urol 55 2009 761 769
45. J.I. Epstein, Z. Feng, B.J. Trock, and P.M. Pierorazio Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades Eur Urol 61 2012 1019 1024
46. J.B. Eifler, Z. Feng, and B.M. Lin et al. An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011 BJU Int 111 2013 22 29
47. A. Briganti, A. Larcher, and F. Abdollah et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores Eur Urol 61 2012 480 487
48. A. Briganti, P. Karakiewicz, and F.K. Chun et al. Percentage of positive biopsy cores can improve the ability to predict lymph node invasion in patients undergoing radical prostatectomy and extended pelvic lymph node dissection Eur Urol 51 2007 1573 1581
49. J. Hansen, M. Rink, and M. Bianchi et al. External validation of the updated Briganti nomogram to predict lymph node invasion in prostate cancer patients undergoing extended lymph node dissection Prostate 73 2013 211 2118
50. A. Heidenreich, D. Pfister, D. Thüer, and B. Brehmer Percentage of positive biopsies predicts lymph node involvement in men with low-risk prostate cancer undergoing radical prostatectomy and extended pelvic lymphadenectomy BJU Int 107 2011 220 225
51. F. Abdollah, M. Sun, and R. Thuret et al. Lymph node count threshold for optimal pelvic lymph node staging in prostate cancer Int J Urol 19 2012 645 651
52. A. Briganti, J.R. Karnes, and L.F. Da Pozzo et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy Eur Urol 55 2009 261 270
53. M.C. Schumacher, F.C. Burkhard, G.N. Thalmann, A. Fleischmann, and U.E. Studer Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy Eur Urol 54 2008 344 352
54. G. Gandaglia, N. Suardi, and A. Gallina et al. Extended pelvic lymph node dissection does not affect erectile function recovery in patients treated with bilateral nerve-sparing radical prostatectomy J Sex Med 9 2012 1287 1294
55. F. Abdollah, M. Sun, and A. Briganti et al. Critical assessment of the European Association of Urology guideline indications for pelvic lymph node dissection at radical prostatectomy BJU Int 108 2011 1769 1775
56. M.D. Shelley, S. Kumar, T. Wilt, J. Staffurth, B. Coles, and M.D. Mason A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma Cancer Treat Rev 35 2009 9 17
57. K.N. Chi, J.L. Chin, E. Winquist, L. Klotz, F. Saad, and M.E. Gleave Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer J Urol 180 2008 565 570
58. E.M. Messing, J. Manola, J. Yao Eastern Cooperative Oncology Group study EST 3886 Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy Lancet Oncol 7 2006 472 479
59. P. Warde, M. Mason, K. Ding NCIC CTG.P.R.3/MRC UK PR07 investigators Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial Lancet 378 2011 2104 2111
60. P.E. Spiess, A.K. Lee, and J.E. Busby et al. Surgically managed lymph node-positive prostate cancer: does delaying hormonal therapy worsen the outcome? BJU Int 99 2007 321 325
61. S.A. Boorjian, R.H. Thompson, and S. Siddiqui et al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era J Urol 178 2007 864 870
62. P. Iversen, M.P. Wirth, W.A. See Casodex Early Prostate Cancer Trialists' Group Is the efficacy of hormonal therapy affected by lymph node status? Data from the bicalutamide (Casodex) early prostate cancer program Urology 63 2004 928 933
63. D.G. McLeod, P. Iversen, W.A. See, T. Morris, J. Armstrong, M.P. Wirth Casodex Early Prostate Cancer Trialists' Group Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer BJU Int 97 2006 247 254
64. M.D. Shelley, S. Kumar, B. Coles, T. Wilt, J. Staffurth, and M.D. Mason Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials Cancer Treat Rev 35 2009 540 546
65. N. Mottet, J. Bellmunt, and M. Bolla et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer Eur Urol 59 2011 572 583
66. A. Briganti, R.J. Karnes, and L.F. Da Pozzo et al. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis Eur Urol 59 2011 832 840
67. L.F. Da Pozzo, C. Cozzarini, and A. Briganti et al. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy Eur Urol 55 2009 1003 1011
68. M. Froehner, A. Scholz, R. Koch, O.W. Hakenberg, G.B. Baretton, and M.P. Wirth Competing mortality contributes to excess mortality in patients with poor-risk lymph node-positive prostate cancer treated with radical prostatectomy Urol Int 89 2012 148 154
69. A. Briganti, M. Spahn, S. Joniau on behalf of the European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT) Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis Eur Urol 63 2013 693 701
70. S. Daneshmand, M.L. Quek, and J.P. Stein et al. Prognosis of patients with lymph-node positive prostate cancer following radical prostatectomy: long-term results J Urol 172 2004 2252 2255